Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans.
Mamidi RN, Cuyckens F, Chen J, Scheers E, Kalamaridis D, Lin R, Silva J, Sha S, Evans DC, Kelley MF, Devineni D, Johnson MD, Lim HK. Mamidi RN, et al. Drug Metab Dispos. 2014 May;42(5):903-16. doi: 10.1124/dmd.113.056440. Epub 2014 Feb 25. Drug Metab Dispos. 2014. PMID: 24568888 Clinical Trial.
Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib.
Hemeryck A, Geerts R, Monbaliu J, Hassler S, Verhaeghe T, Diels L, Verluyten W, van Beijsterveldt L, Mamidi RN, Janssen C, De Coster R. Hemeryck A, et al. Among authors: mamidi rn. Cancer Chemother Pharmacol. 2007 Nov;60(6):777-87. doi: 10.1007/s00280-007-0424-9. Epub 2007 Feb 7. Cancer Chemother Pharmacol. 2007. PMID: 17285316
Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN, Weng S, Stellar S, Wang C, Yu N, Huang T, Tonelli AP, Kelley MF, Angiuoli A, Fung MC. Mamidi RN, et al. Cancer Chemother Pharmacol. 2010 Nov;66(6):1173-84. doi: 10.1007/s00280-010-1406-x. Epub 2010 Jul 27. Cancer Chemother Pharmacol. 2010. PMID: 20661737
Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.
De Zwart L, Snoeys J, Jacobs F, Li LY, Poggesi I, Verboven P, Goris I, Scheers E, Wynant I, Monshouwer M, Mamidi RNVS. De Zwart L, et al. Among authors: mamidi rnvs. CPT Pharmacometrics Syst Pharmacol. 2021 Sep;10(9):1107-1118. doi: 10.1002/psp4.12682. Epub 2021 Aug 11. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34273250 Free PMC article.
46 results